Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 11;15:197–207. doi: 10.2147/JAA.S337236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Yang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

LncRNA CASC2 serves as a ceRNA of miR-31-5p. (A) Targeting relationship between CASC2 and miR-31-5p. (B) Luciferase activity of cells under different treatment. (C) Relative miR-31-5p levels in different cell groups. (D) Serum miR-31-5p levels in clinical serum samples. (E) Serum CASC2 showed a negative correlation with miR-31-5p levels in all study subjects. ***P < 0.001 when compared with the control group; ^&&P < 0.01, ^&&&P < 0.001 when compared with PDGF-BB group.

Abbreviations: CASC2, cancer susceptibility candidate 2; NC, negative control; WT, wide type; MUT, mutant type; PDGF-BB, platelet-derived growth factors BB.